{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
IDEXX Laboratories, Inc.
IDEXX Laboratories Hits New 52-Week High of $734.64, Up 42.24%
IDEXX Laboratories, Inc. has achieved a new 52-week high, reflecting its strong performance with a one-year growth rate significantly exceeding that of the S&P 500. The company, with a market cap of USD 66,543 million, showcases solid financial metrics, including a high return on equity and manageable debt levels.
Is IDEXX Laboratories, Inc. overvalued or undervalued?
As of October 17, 2025, IDEXX Laboratories, Inc. is fairly valued with a P/E ratio of 60, an EV to EBITDA of 42.53, and a PEG ratio of 11.32, indicating a premium compared to peers like Abbott Laboratories and Thermo Fisher Scientific, while outperforming the S&P 500 with a year-to-date return of 53.69%.
IDEXX Laboratories, Inc. Experiences Revision in Its Stock Evaluation Amid Strong Performance Metrics
IDEXX Laboratories, Inc. has recently adjusted its valuation, showcasing a P/E ratio of 60 and a robust Return on Capital Employed of 51.10%. Compared to peers like Abbott Laboratories and Thermo Fisher Scientific, IDEXX's stock has demonstrated strong year-to-date performance, significantly exceeding the S&P 500.
Is IDEXX Laboratories, Inc. overvalued or undervalued?
As of October 17, 2025, IDEXX Laboratories, Inc. is fairly valued with a P/E ratio of 60 and an EV to EBITDA of 42.53, outperforming the S&P 500 with a year-to-date return of 53.69%, but trading at a premium compared to peers like Abbott Laboratories and Thermo Fisher Scientific.
Is IDEXX Laboratories, Inc. overvalued or undervalued?
As of October 17, 2025, IDEXX Laboratories, Inc. is fairly valued with a P/E ratio of 60 and a strong ROE of 61.71%, outperforming the S&P 500 with a 38.13% return, despite having a higher P/E than some peers like Abbott Laboratories and Thermo Fisher Scientific.
IDEXX Laboratories, Inc. Experiences Evaluation Adjustment Amidst Mixed Market Indicators
IDEXX Laboratories, Inc. has recently adjusted its market evaluation, with its stock priced at $627.78. The company has shown strong performance over the past year, achieving a 31.43% return, significantly outperforming the S&P 500. Technical indicators present a mixed outlook, reflecting varying trends across different time frames.
Is IDEXX Laboratories, Inc. technically bullish or bearish?
As of October 3, 2025, IDEXX Laboratories, Inc. shows a mildly bullish trend supported by monthly MACD and KST indicators, despite short-term bearish signals from weekly MACD and RSI, while outperforming the S&P 500 year-to-date and over the past year, but lagging in longer periods.
Is IDEXX Laboratories, Inc. technically bullish or bearish?
As of October 3, 2025, IDEXX Laboratories, Inc. has a mildly bullish technical trend, supported by bullish MACD and KST indicators, despite mixed signals from the RSI and Dow Theory, and it has significantly outperformed the S&P 500 year-to-date and over the past year.
Is IDEXX Laboratories, Inc. technically bullish or bearish?
As of October 3, 2025, IDEXX Laboratories, Inc. shows a mildly bullish trend with mixed signals from technical indicators, having outperformed the S&P 500 year-to-date and over the past year, despite recent underperformance.
IDEXX Laboratories Hits Day High with Strong 3.35% Intraday Surge
IDEXX Laboratories, Inc. has shown strong performance, gaining 3.35% today and achieving an intraday high of USD 639.53. Over the past year, the company has returned 25.51%, outperforming the S&P 500. IDEXX's financial metrics indicate efficient management and strong market confidence, with high institutional holdings at 99.77%.
IDEXX Laboratories Experiences Revision in Stock Evaluation Amid Strong Market Performance
IDEXX Laboratories, Inc. has recently revised its evaluation amid changing market conditions. The company’s stock price reflects a significant increase, and it has outperformed the S&P 500 over the past year. Despite mixed short-term signals, IDEXX demonstrates strong long-term growth potential and resilience in the Pharmaceuticals & Biotechnology sector.
Is IDEXX Laboratories, Inc. technically bullish or bearish?
As of September 26, 2025, IDEXX Laboratories, Inc. shows a bullish technical trend supported by positive MACD and KST indicators, despite a bearish RSI and mixed short-term signals, while outperforming the S&P 500 year-to-date and over the past year.
Is IDEXX Laboratories, Inc. technically bullish or bearish?
As of September 26, 2025, IDEXX Laboratories, Inc. shows a bullish trend supported by positive MACD and KST indicators, despite a bearish RSI and mixed signals from Dow Theory, while outperforming the S&P 500 year-to-date and over one year, but underperforming over the last five and ten years.
IDEXX Laboratories Hits Day Low of $621.36 Amid Price Pressure
IDEXX Laboratories, Inc. saw a decline in stock price despite strong performance metrics, including a 51.7% year-to-date return and a 23.4% increase over the past year. The company boasts a high return on capital employed and a low debt-to-EBITDA ratio, indicating effective capital management and strong investor confidence.
Is IDEXX Laboratories, Inc. technically bullish or bearish?
As of July 24, 2025, IDEXX Laboratories, Inc. shows a bullish technical trend supported by positive MACD and KST indicators, despite a bearish weekly RSI, while outperforming the S&P 500 with a year-to-date return of 58.55%.
Is IDEXX Laboratories, Inc. overvalued or undervalued?
As of August 8, 2025, IDEXX Laboratories, Inc. is fairly valued with a P/E ratio of 60 and strong year-to-date returns of 58.55%, despite trading at a premium compared to peers like Abbott Laboratories and Thermo Fisher Scientific.
Is IDEXX Laboratories, Inc. overvalued or undervalued?
As of May 1, 2025, IDEXX Laboratories, Inc. is considered overvalued due to high financial ratios, including a P/E of 60 and an EV to EBITDA of 42.53, and has underperformed the S&P 500 with a return of 5.83% compared to the index's 10.26%.
Who are in the management team of IDEXX Laboratories, Inc.?
As of March 2022, the management team of IDEXX Laboratories, Inc. includes Lawrence Kingsley (Independent Chairman), Jonathan Mazelsky (President & CEO), and several independent directors: Jonathan Ayers, Bruce Claflin, Asha Collins, Stuart Essig, and Rebecca Henderson. They oversee the company's strategic direction and operations.
What does IDEXX Laboratories, Inc. do?
IDEXX Laboratories, Inc. develops and distributes products for veterinary, livestock, and water testing markets, with recent net sales of $998 million and a market cap of $53.28 billion. Key financial metrics include a P/E ratio of 60.00 and a return on equity of 61.71%.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
